Inexia

Inexia is a biotechnology company focused on developing novel treatments for neurological diseases, specifically targeting the orexin pathway. Founded as a collaboration between Sosei Heptares and Medicxi, the company leverages Sosei Heptares' GPCR structure-based drug design platform to create potent orexin receptor agonists. These candidates are designed for intranasal delivery using OptiNose's Exhalation Delivery System to optimize brain penetration and efficacy. The company's primary focus is on treating Narcolepsy Type 1 and other disorders characterized by excessive daytime sleepiness. In 2021, Inexia was acquired by Centessa Pharmaceuticals as part of its formation, merging its assets into Centessa's broader neuroscience portfolio.